^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DLL3 expression

    i
    Other names: DLL3, Delta Like Canonical Notch Ligand 3, Drosophila Delta Homolog 3, Delta-Like Protein 3, Delta3, Delta (Drosophila)-Like 3, Delta-Like 3 (Drosophila), Delta-Like 3, SCDO1
    Entrez ID:
    10683
    Related biomarkers:
    Expression
    1d
    A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs ( SPECTRAL-1 ) (clinicaltrials.gov)
    P1, N=110, Not yet recruiting, Moonlight Bio, Inc
    New P1 trial • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    8d
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Not yet recruiting, Boehringer Ingelheim
    New P3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    15d
    Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer. (PubMed, JCO Precis Oncol)
    Prostate cancer exhibits distinct molecular subtypes defined by AR signaling activity, NEPC transcriptional profiles, and genomic alterations. These biologically and clinically relevant subgroups provide a framework for precision oncology approaches and inform patient selection for biomarker-driven trials such as the ongoing PREDICT study (ClinicalTrials.gov identifier: NCT06632977).
    Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • DLL3 (Delta Like Canonical Notch Ligand 3) • FOLH1 (Folate hydrolase 1) • SPOP (Speckle Type BTB/POZ Protein)
    |
    PTEN mutation • DLL3 expression
    16d
    DLL3-Targeted PET/CT in Neuroendocrine Carcinoma (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Xiamen University
    New trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    19d
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)
    1m
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC (clinicaltrials.gov)
    P1, N=138, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    1m
    CSET 2024/4014: Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), with biomarker analysis to characterize response/resistance (UNLOCK TARLATAMAB) (2024-515847-47-00)
    P1/2, N=40, Recruiting, Institut Gustave Roussy
    New P1/2 trial
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • DLL3 (Delta Like Canonical Notch Ligand 3) • NCAM1 (Neural cell adhesion molecule 1)
    |
    DLL3 expression • DLL3 positive
    |
    Imdelltra (tarlatamab-dlle)
    1m
    GCO-003 TARLANEC: Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs) (2024-515948-23-00)
    P2/3, N=129, Recruiting, Intergroupe Francophone De Cancerologie Thoracique
    New P2/3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • docetaxel • 5-fluorouracil • temozolomide • irinotecan • dacarbazine • topotecan • Imdelltra (tarlatamab-dlle)
    1m
    RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab (2024-514327-42-00)
    P1/2, N=87, Recruiting, Grupo Espanol De Tumores Neuroendocrinos
    New P1/2 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    5-fluorouracil • Imdelltra (tarlatamab-dlle)
    1m
    VHH-based CAR-T cells targeting DLL3 show high efficacy in small-cell lung cancer models. (PubMed, Mol Cancer Ther)
    Moreover, these HM-CAR T cells demonstrated significant antitumor efficacy in vivo. This study highlights effective strategies for developing DLL3-specific VHHs and their application in CAR T therapy, which supports their clinical potential as a promising immunotherapeutic approach for cancers that express DLL3.
    Preclinical • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    1m
    TARLANEC: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (clinicaltrials.gov)
    P3, N=129, Recruiting, Intergroupe Francophone de Cancerologie Thoracique | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Aug 2030 | Initiation date: Sep 2025 --> Feb 2026 | Trial primary completion date: Sep 2028 --> Feb 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    docetaxel • 5-fluorouracil • irinotecan • Imdelltra (tarlatamab-dlle)
    2ms
    RAGNAR: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab (clinicaltrials.gov)
    P2, N=87, Recruiting, Grupo Espanol de Tumores Neuroendocrinos | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    5-fluorouracil • irinotecan • leucovorin calcium • Imdelltra (tarlatamab-dlle)